# KEYNOTE-C11 (NCT05008224)

> Study of Safety and Efficacy of Pembrolizumab and Chemotherapy in Participants With Newly Diagnosed Classical Hodgkin Lymphoma (cHL) (MK-3475-C11/KEYNOTE-C11)

No report yet. It can be ordered.

- Drugs tested: pembrolizumab plus AVD; pembrolizumab plus escBEACOPP
- Indication: newly diagnosed classical Hodgkin lymphoma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05008224
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: Merck Sharp & Dohme LLC
- Conditions: Classical Hodgkin Lymphoma
- Interventions: Pembrolizumab; Doxorubicin; Vinblastine; Dacarbazine; Bleomycin; Etoposide; Cyclophosphamide; Vincristine; Procarbazine; Prednisone
- Enrollment: 146
- Primary outcome: Complete Response (CR) Rate at the End of Study Intervention as Assessed by Blinded Independent Central Review (BICR) Per Lugano 2014 Response Criteria

## Indexed commentary on KEYNOTE-C11 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 2
- Podcasts: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=keynote-c11-nct05008224